External Advisory Board

Eric Winer, MD, is the Director of Yale Cancer Center, as well as President and Physician-in-Chief of the Smilow Cancer Hospital Yale New Haven Health System. An internationally renowned medical oncologist and expert in breast cancer, he has conducted clinical trials that have changed the face of the disease. His work has impacted almost all aspects of breast cancer.

Eileen Dolan is the current Deputy Director of the University of Chicago Medicine Comprehensive Cancer Center. Eileen has been in this position since March of 2022. Prior to their current role, Dolan served as the Associate Director for Education at the University of Chicago Comprehensive Cancer Center from January 2014 to March 2022. Dolan has also served as the co-Leader of Pharmacogenomics and Experimental Therapeutics at the University of Chicago Comprehensive Cancer Center from January 2001 to July 2020.

Pamela C. Hull, Ph.D., is the Associate Director of Population Science and Community Impact in the University of Kentucky (UK) Markey Cancer Center (MCC), and an Associate Professor of Behavioral Science in the UK College of Medicine. As Associate Director, she leads the MCC Community Impact Office to oversee MCC’s community outreach and engagement (COE) functions, and she oversees MCC’s population science research agenda and infrastructure. The mission of the MCC Community Impact Office is to accelerate the translation of scientific research findings to everyday practice in community and clinical settings, across the cancer care continuum from prevention through survivorship.

Anita Kinney is a professor in the Department of Biostatistics and Epidemiology and director of the Center for Cancer Health Equity at the School of Public Health. She also serves as the associate director for cancer health equity and engagement at Rutgers Cancer Institute of New Jersey and director of ScreenNJ, a statewide cancer prevention and screening program. In these roles, Dr. Kinney seeks to advance cancer health equity in cancer prevention and care delivery through community partnerships and engagement, outreach, and a team science approach. Dr. Kinney has sustained research funding by the National Institutes of Health for nearly 30 years with a focus on cancer prevention, community and clinical genetics, and survivorship.

Scott Kopetz is is a physician-scientist who enjoys the intellectual challenges of the lab, the emotional engagement of the clinic and has the motivation to bridge the two. Dr. Kopetz is the Deputy Chair for Translational Research, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX. He is Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine and Leader, Department of Cancer Center Support Grant, GI Program. He is also TRACTION Medical Director, Division of Therapeutics Discovery Division and Associate Vice President for Translational Integration.

Darin Latimore is Yale School of Medicine’s first deputy dean for diversity and inclusion and its first chief diversity officer. He is devoted to increasing diversity within medical and academic spaces and to improving the climate of Yale School of Medicine’s learning and working environments. He is responsible for developing and implementing a comprehensive strategic plan for furthering diversity, equity, and inclusion (DEI) at the school, which includes a focus on recruitment and retention of faculty and students from backgrounds that have been historically underrepresented in science and medicine.

J. Jack Lee is Professor of Biostatistics at the University of Texas MD Anderson Cancer Center in Houston, Texas. Dr. Lee is also a Statistical Editor for the Journal of the National Cancer Institute and Cancer Prevention Research. He is a Fellow of the American Statistical Association. Dr. Lee’s areas of research interest include design and analysis of clinical trials, survival analysis, longitudinal data analysis, statistical computation/graphics, statistical methods for determining drug interaction in combination studies, and cancer chemoprevention. Dr. Lee has been working on the development and application of innovative Bayesian methods for cancer clinical trials. He also actively participates in many multidisciplinary translational research in head/neck and lung cancer teams funded by National Institute of Health (NIH) and the Department of Defense (DoD). He has particular interests in incorporating multiple biomarkers and adaptive designs to develop more efficient and ethical clinical trials.

Scott M. Lippman, MD, is associate vice chancellor for cancer research and care, professor of medicine at UC San Diego School of Medicine, and holds the Chugai pharmaceutical chair in cancer. He is also an adjunct professor at the Salk Institute, the Sanford-Burnham Medical Research Institute and MD Anderson Cancer Center. Dr. Lippman has been recognized in every major "Top Doctor" listing including U.S. News & World Report. He has received numerous awards, including the American Cancer Society of Clinical Oncology (ASCO) Award, the American Association for Cancer Research (AACR) Award and the ASCO Statesman Award.

Pat LoRusso brings more than 25 years of expertise in medical oncology, drug development, and early phase clinical trials. Prior to her Yale appointment, she served in numerous leadership roles at Wayne State University’s Barbara Karmanos Cancer Institute, most recently as director of the Phase I Clinical Trials Program and of the Eisenberg Center for Experimental Therapeutics.

Stephen D. Nimer, M.D., is the director of the National Cancer Institute (NCI)-designated Sylvester Comprehensive Cancer Center. He is also the executive dean for research and a professor of medicine, biochemistry and molecular biology at the University of Miami Miller School of Medicine. Dr. Nimer's career spans more than 30 years in clinical care, research, administration and leadership. A physician-scientist in the field of hematology-oncology and cancer research, Dr. Nimer has authored more than 300 scientific publications and holds numerous awards including the Oscar de La Renta Endowed Chair in Cancer Research, the Irma T. Hirschl Career Scientist Award and he received the E. Donnall Thomas Award in 2015 from the Bone Marrow Foundation.

Jerome Ritz is Executive Director of the Connell-O'Reilly Cell Manipulation Core Facility (CMCF) and a Professor of Medicine at Harvard Medical School. The CMCF provides hematopoietic stem cells for patients who are undergoing hematopoietic stem cell transplantation and manufactured cellular products of various types for patients enrolled on clinical trials evaluating novel cellular therapies for cancer. Dr. Ritz is a member of the Executive Committee of the Dana-Farber/Harvard Cancer Center and the Associate Director for Core Facilities at DF/HCC. He is a Co-Director of the Cancer Vaccine Center at the Dana-Farber Cancer Institute and a member of the Executive Committee of the Harvard Stem Cell Institute. Dr. Ritz's current laboratory research focuses on immune reconstitution after hematopoietic stem cell transplantation, cellular therapies and immunotherapy of cancer.

Elena Martinez, PhD is a Professor in the Department of Family Medicine and Public Health, Division of Preventive Medicine. She holds the Sam M. Walton Endowed Chair for Cancer Research and Co-leads the Reducing Cancer Disparities Program at the Moores Cancer Center. Dr. Martinez holds a PhD in Epidemiology and a Master’s in Public Health. 

As associate director for administration at University of Florida Health Cancer Center, Alison Ivey, MBA, RN,  oversees all administrative functions of the Cancer Center. Ivey has a Bachelor of Arts in anthropology from the University of Florida, a Bachelor of Nursing from Johns Hopkins University, a Master of Science in Clinical Research Management from Arizona State University and a Master of Business Administration with a specialization in data analytics from Louisiana State – Shreveport. She is an active member of several professional groups and societies, including the American Society of Clinical Oncology, the Oncology Nursing Society and the Society of Clinical Research Associates. She has held specialty certifications in both oncology nursing and clinical research for over 15 years.